Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.

摘要: Aims/introduction Non-alcoholic fatty liver disease (NAFLD) is often observed in individuals with type 2 diabetes mellitus, and it known that the presence of mellitus leads to aggravation NAFLD. The aim this study was compare possible effects three kinds oral hypoglycemic agents on NAFLD mellitus. Materials methods We carried out a prospective clinical trial (a randomized open-label study) patients A total 98 were randomly allocated either dapagliflozin (n = 32), pioglitazone 33) or glimepiride group, took these drugs for 28 weeks. primary end-point change liver-to-spleen ratio abdominal computed tomography. Results There no difference baseline characteristics among groups. Dapagliflozin, ameliorated hyperglycemia similarly. Bodyweight visceral fat area significantly decreased only group. Serum adiponectin levels markedly increased group compared other two Dapagliflozin pioglitazone, but not glimepiride, ratio, comparable. Conclusions present showed decrease increase level contributed improvement Furthermore, exerted equivalent beneficial although seemed had different mechanisms action.